Litcius/Paper detail

Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial

Thomas Bachelot, Thomas Filleron, Ivan Bièche, Mónica Arnedos, Mario Campone, Florence Dalenc, Florence Coussy, Marie‐Paule Sablin, Marc Debled, Claudia Lefeuvre‐Plesse, Anthony Gonçalvès, Marie‐Ange Mouret‐Reynier, William Jacot, Benoît You, Philippe Barthélémy, Benjamin Verret, Nicolás Isambert, X. Tchiknavorian, Christelle Lévy, Jean‐Christophe Théry, Tifenn L’Haridon, Jean-­Marc Ferrero, Alice Mège, Francesco Del Piano, Étienne Rouleau, Alicia Tran-Dien, Julien Adam, Amélie Lusque, Marta Jimenez, Alexandra Jacquet, Ingrid Garberis, Fabrice André

2021Nature Medicine158 citationsDOI

Topics & Concepts

DurvalumabMedicineBreast cancerChemotherapyOncologyMetastatic breast cancerRandomized controlled trialInternal medicineCancerImmunotherapyNivolumabHER2/EGFR in Cancer ResearchCancer Immunotherapy and BiomarkersAdvanced Breast Cancer Therapies